Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« The Big Time | Main | Worst Animal Model: Nominations Are Open »

April 19, 2007

Let A Thousand Flowers Bloom

Email This Entry

Posted by Derek

If you want to see a bunch of press releases from biotech companies that you've never, ever heard of in your life, just go over to Google News and type in "AACR", sorting by date. That meeting just wound up, and it was the usual fiesta of early- and late-stage oncology data.

But cancer is an odd field for drug development. There are (relatively speaking) many more targets, since the disease itself is a huge fragmented bunch of different indications. And we don't have nearly enough knowledge to have a good idea - any idea, most of the time - about which of these targets are more likely to work, and against which forms of cancer. The trials themselves tend to be smaller (thus cheaper), since the course of the disease is often so relentless, and if you get a drug to market, you don't have to take out ads on the Super Bowl to promote it to oncologists.

All that means that the entry barrier to the field is lower, and there are plenty of niches. And boy, are they filled by a lot of microscopic companies. I keep up with things fairly well, but there are outfits presenting at AACR that might as well be from the asteroid belt for all I know about 'em. . ..

Comments (5) + TrackBacks (0) | Category: Cancer


COMMENTS

1. Hap on April 19, 2007 11:49 AM writes...

I hope the same thing that happened to the thousand flowers doesn't happen to the thousand cancer drugs...

Permalink to Comment

2. David Young MD on April 19, 2007 4:10 PM writes...

Yes, I was at the meeting. Lots and lots of targets. Seems that every receptor tyrosine kinase studied. Many new companies being named and ideas that will take 6 to 8 years to sort out. I don't know how they hang on for so long.

I keep a list of these investigational drugs for cancer and my list is 700 plus. Having attended the AACR, I will have to add another 50 to 100 new investiational drugs. Of course, some of the compounds tests have not advanced beyond cell cultures, so they would not really qualify as a contender yet.

Permalink to Comment

3. Retired Med. Chemist on April 20, 2007 9:01 PM writes...

Yes, this is the area you can do some good science without burning a hugh hole in your pocket. If you get a hit, some Pharma will
likely license it, for the same lower cost reason.
They can get an indication from relatively small
trials and off they run.
Sometimes, as in the case of Kosan, they licensed
from NCI a pair of good Hsp90 inhibitors and
are in Phase 2-3 in a couple of years.

Permalink to Comment

4. Joseph Jones on April 23, 2007 11:30 AM writes...

Some of the web casts on their website seem to be quite promising though.

I've seen a few of those micro companies even going public on early cell culture/Xenographs data, assuming they hold the next billion dollar blockbuster drug.

Being a new broker, I was wondering if I could find some help on investigating(valuating?) such companies from an investor perspective. There have to be some with reality and/or potential. Anyway I enjoyed reading your blog and thought I should write here.

Permalink to Comment

5. wcw on April 23, 2007 5:34 PM writes...

Valuing them as a broker?

1) have your clients index. Yeah, you won't get paid, but..
2) estimate the potential market. guesstimate the chance of success. divide this latter by 10. or 100. multiply. discount at a high rate. compare to the market cap. voila, you have a valuation
3) notice how much of crapshoot this is
4) see step 1

Now, I have made and lost money on small biotechs, but I'll tell you one thing: I would never have a widow or orphan invest in a single one, ever.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Try Some Reactions. Actually, Try Them All.
Holiday Blogging
Reaction Discovery Reviewed
Deadly Incompetence in India
The Cost of Developing A New Drug
Virtual Covalent Screening
Amgen Claims It All
More From The Bottom of the Publishing Barrel